title: Squamous cell carcinoma antigen production in nasal inverted papilloma.
abstract: BACKGROUND
  The clinical importance of serum squamous cell carcinoma antigen (SCCA) and SCCA subclasses has not been established for treating inverted papilloma (IP). The aim of this study was to clarify the clinical importance of serum SCCA and its subclasses in IP, compared  with maxillary squamous cell carcinoma and inflammatory disease.
  
  
  METHODS
  Serum SCCA was measured in 22 patients with IP (IP group), 11 with maxillary squamous cell carcinoma (carcinoma group), and 22 with inflammatory disease (inflammatory group). mRNA expression of SCCA  subclasses was examined using quantitative real-time polymerase chain reaction.
  
  
  RESULTS
  In the IP group, 81.8% showed elevated serum SCCA, and 90.3% with recurrent IP showed elevated SCCA. The preoperative SCCA value (mean ± SD, 3.99 ± 4.39) in the IP group  was significantly higher than in the carcinoma (1.28 ± 0.88; p = 0.012) and inflammatory (0.60 ± 0.31; p < 0.001) groups. mRNA expression of SCCA1 and SCCA2 in the IP group was higher than in the carcinoma and inflammatory groups. The SCCA2/SCCA1 ratio of mRNA expression (0.11  ± 0.06) in the IP group was similar to that (0.11 ± 0.09) in the inflammatory group, although the ratio (0.20 ± 0.12) in the carcinoma group was significantly higher than in the IP and inflammatory groups. The receiver operating characteristic curve analysis for the SCCA2/SCCA1  ratio to detect carcinoma yielded an area under the curve of 0.760 (95% confidence interval, 0.626-0.894).
  
  
  CONCLUSIONS
  The serum level of SCCA is effective for detecting IP, including recurrent IP. In contrast, the SCCA2/SCCA1 ratio is useful for detecting squamous  cell carcinoma among other sinonasal diseases.
authors.affiliation: Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. suzuki@med.u-ryukyu.ac.jp
authors.forename: Mikio
authors.initials: M
authors.lastname: Suzuki
authors.forename: Zeyi
authors.initials: Z
authors.lastname: Deng
authors.forename: Masahiro
authors.initials: M
authors.lastname: Hasegawa
authors.forename: Takayuki
authors.initials: T
authors.lastname: Uehara
authors.forename: Asanori
authors.initials: A
authors.lastname: Kiyuna
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Maeda
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009669:Nose Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D018308:Papilloma, Inverted / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D011379:Prognosis; D012008:Recurrence; D015843:Serpins / Q000097:blood*; D016896:Treatment Outcome; D015854:Up-Regulation
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D015843:Serpins; C051072:squamous cell carcinoma-related antigen